Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| FTLF | PRESS-RELEASE | mixed | 6/10 | FitLife Brands reported Q1 2026 revenue of $25.3M (+59% YoY), beating the $24.9M consensus, and EPS of $0.17 diluted, be | May 14, 2026 |
| BFRI | PRESS-RELEASE | bullish | 7/10 | Biofrontera reported Q1 2026 revenue of $10.1M (+17% YoY), gross margins expanding to ~80% from ~62%, and near-zero cash | May 14, 2026 |
| CRMD | PRESS-RELEASE | bullish | 7/10 | CorMedix reported Q1 2026 revenue of $127.4M (21% above $105M consensus) and GAAP EPS of $0.43 diluted (30% above $0.33 | May 14, 2026 |
| HCWB | PRESS-RELEASE | bullish | 6/10 | HCW Biologics announced preclinical data showing its fusion immunotherapeutic HCW11-040 prevented bronchopulmonary dyspl | May 14, 2026 |
| INKT | PRESS-RELEASE | bullish | 7/10 | MiNK Therapeutics announced the initiation of a randomized Phase 2 trial (C-1300-02) evaluating its off-the-shelf iNKT c | May 14, 2026 |
| CGTX | PRESS-RELEASE | neutral | 3/10 | Cognition Therapeutics announced a second philanthropic donation to extend its expanded access program (EAP) for zervime | May 14, 2026 |
| CLRB | PRESS-RELEASE | bullish | 6/10 | Cellectar Biosciences reported Q1 2026 EPS of -$1.33, beating the -$1.89 consensus, but remains pre-revenue. The key cat | May 14, 2026 |
| XRTX | PRESS-RELEASE | bearish | 6/10 | XORTX Therapeutics priced a public offering of ~2.66M shares at $1.88/share for $5M gross proceeds, representing massive | May 14, 2026 |
| CABA | PRESS-RELEASE | neutral | 4/10 | Cabaletta Bio reported Q1 2026 EPS of -$0.40, a 3.1% miss vs consensus of -$0.39, with no revenue. The miss is marginal | May 14, 2026 |
| LRMR | PRESS-RELEASE | bullish | 7/10 | Larimar Therapeutics reported Q1 2026 EPS of -$0.31, beating consensus of -$0.57 by 45.6%, with no revenue. The company | May 14, 2026 |
| PYXS | PRESS-RELEASE | neutral | 4/10 | Pyxis Oncology reported Q1 2026 EPS of -$0.37, missing consensus of -$0.35 by 5.7%. The clinical-stage biotech has $42.5 | May 14, 2026 |
| HYPD | PRESS-RELEASE | mixed | 6/10 | Hyperion DeFi reported Q1 2026 GAAP net income of $8.8M vs a net loss of $3.5M in Q1 2025, driven by $21.5M in treasury | May 14, 2026 |
| PTHS | PRESS-RELEASE | neutral | 5/10 | Pelthos Therapeutics reported Q1 2026 EPS of -$3.09, beating the -$3.58 consensus by 13.7%, on total revenue of $10.9M ( | May 14, 2026 |
| IVVD | PRESS-RELEASE | neutral | 5/10 | Invivyd reported Q1 2026 PEMGARDA revenue of $13.7M (+22% YoY), beating consensus estimates on both revenue ($13.7M vs $ | May 14, 2026 |
| GHRS | PRESS-RELEASE | mixed | 6/10 | GH Research reported Q1 2026 EPS of -$0.31, wider than the -$0.26 consensus estimate (a ~19% miss on a GAAP basis), and | May 14, 2026 |
| AUTL | PRESS-RELEASE | mixed | 6/10 | Autolus reported Q1 2026 AUCATZYL net product revenue of $26.2M (vs $9.0M YoY), achieving its first positive gross margi | May 14, 2026 |
| NRXP | PRESS-RELEASE | neutral | 1/10 | NRx Pharmaceuticals, Inc. announced it will report its Q1 2026 results on May 18, 2026. | May 14, 2026 |
| TNXP | PRESS-RELEASE | neutral | 2/10 | Tonix Pharmaceuticals announced a poster presentation at ISPOR 2026 on a retrospective claims study characterizing fibro | May 14, 2026 |
| BIIB | PRESS-RELEASE | mixed | 6/10 | Biogen reported mixed Phase 2 CELIA results for diranersen in early Alzheimer's disease. The study missed its primary en | May 14, 2026 |
| FENC | PRESS-RELEASE | bullish | 6/10 | Fennec Pharmaceuticals reported Q1 2026 revenue of $15.1M (+73% YoY) and GAAP net income of $0.01 per diluted share, ver | May 14, 2026 |
| EDIT | PRESS-RELEASE | bullish | 5/10 | Editas Medicine presented preclinical data for EDIT-401 at ASGCT, showing ≥90% mean LDL-C reduction in NHPs durable thro | May 14, 2026 |
| LNZA | PRESS-RELEASE | bullish | 6/10 | LanzaTech reported Q1 2026 EPS of -$1.77, beating consensus of -$2.88 by 38.5%, and revenue of $12.0M (vs $12.1M est, in | May 14, 2026 |
| PPCB | PRESS-RELEASE | neutral | 4/10 | Propanc Biopharma announced a 1-for-25 reverse stock split approved by the board on March 16, 2026, effective May 18, 20 | May 13, 2026 |
| RVPH | PRESS-RELEASE | bearish | 7/10 | Reviva Pharmaceuticals reported Q1 2026 net loss of $3.2M ($0.46/share), narrower than the year-ago $6.4M loss ($2.61/sh | May 13, 2026 |
| ONCO | PRESS-RELEASE | neutral | 3/10 | Onconetix provided a Q1 2026 operational update highlighting new clinical publications for Proclarix®, initiation of the | May 13, 2026 |
| TARA | PRESS-RELEASE | neutral | 4/10 | Protara Therapeutics reported Q1 2026 net loss of $0.31 per share, beating consensus estimates of $0.37 loss, with cash | May 13, 2026 |
| IPSC | PRESS-RELEASE | neutral | 4/10 | Century Therapeutics reported Q1 2026 EPS of -$0.11, beating the -$0.17 consensus by 35%, with zero revenue (in line). T | May 13, 2026 |
| SLXN | PRESS-RELEASE | bullish | 5/10 | Silexion Therapeutics announced initiation of GMP manufacturing of SIL204 with Catalent and ethics committee approval fo | May 13, 2026 |
| QUCY | PRESS-RELEASE | neutral | 3/10 | Quantum Cyber announced an exclusive IP license agreement with BP United Inc. for autonomous drone technology, including | May 13, 2026 |
| BCTXL | PRESS-RELEASE | neutral | 3/10 | BriaCell announced the addition of Penn Medicine's Abramson Cancer Center as a clinical trial site for its pivotal Phase | May 13, 2026 |